FDA adcomms to review data on long-term opioid use, overdoses
FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two completed post-marketing studies the agency requested more than a decade ago. The agency is convening ...
FDA advisors next week will discuss the risks of long-term opioid use during a joint-committee meeting that will examine two completed post-marketing studies the agency requested more than a decade ago.
The agency is convening ...
